$SELB SPECULATIVE BUT REWARDING IN SELECTA BIO

*******HOT STOCK ON THE WATCHLIST FOR NEXT WEEK, STRENGTH HAS BEEN BUILDING IN NASDAQ:SELB SINCE JANUARY AND A BREAKOUT IS VERY POSSIBLE SOON. THE HISTOGRAM HAS GONE POSITIVE AND THE MACD IS ABOUT TO CROSS POSITIVELY, WHILE THE RSI IS AT A APEX AND LOOKS LIKE BREAKING OUT TO THE UPSIDE. ALERTS ARE SET FOR BREAK ABOVE THE 50MA WHICH IS CURRENTLY RESISTANCE BUT DROPPING WHILE PRICE IS GAINING MOMENTUM.

EARNINGS TRANSCRIPT HIGHLIGHTS
Revenue recognized for the first quarter of 2019 was less than $0.1 million and was for shipment order under our collaboration agreement with Spark, which compares to no revenue recognized for the first quarter of 2018. Research and development expenses for the first quarter of 2019 were $7.4 million, which compares to $11.1 million for the same period in 2018. The decrease was driven by reduced salaries and benefits as a result of our headcount reduction at the beginning of the first quarter of 2019 combined with expenses incurred for both our Phase II and Phase III clinical programs for SEL-212. General administrative expenses for the first quarter of 2019 were $4.5 million, which compares with $4.7 million for the same period in 2018. The reduction in cost was primarily the result of reduced consulting fees. For the first quarter of 2019, Selecta reported a net loss of $12.1 million or $0.31 per share compared to a net loss of $15.9 million or $0.71 per share for the same period in 2018. As of March 31, 2019, we had approximately $48.7 million in cash, cash equivalents, short-term deposits, investments and restricted cash. We continue to expect that our cash balance is sufficient to fund operations into the first quarter of 2020.

AVERAGE ANALYSTS TARGET PRICE $10.80
AVERAGE ANALYSTS RECOMMENDATION BUY

COMPANY PROFILE
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. it produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.